Professional Education Resource Center

Elevating patient care

The IPC Professional Education Resource Center provides tools and resources for health-care providers, no matter where in the world, to help improve their expertise in treating psoriasis.

On-line CME ProgramsCase-based learning activities

Congress CoveragePsoriasis highlights from major dermatology and psoriasis congresses

Top ManuscriptsExpert perspectives on current research

Psoriasis Review NewsletterPsoriasis highlights from major dermatology and psoriasis congresses

Video LecturesHot topics and challenges cases from congresses around the world

Live Events Satellite symposia at major congresses and 2-day Master Classes

Clinical tools and resources

The following resources have been compiled as a resource for managing psoriasis in clinical practice.

Treatment Guidelines

Compilation of up-to-date guidelines for treating psoriasis

Measurement Tools

Tools for assessing and managing psoriasis

Links of Interest

Links to other dermatology and psoriasis organizations

Articles and Reports Important articles and report on psoriasis

Psoriasis Image Gallery

Over 500 images of psoriasis available for download and use in educational programs

Resources for Your Patients

Coming soon!

Thank you to AbbVie for their support to create the Professional Education Resource Center.

Psoriasis News

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

8/20/2019 10:08:00 AM

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

8/6/2019 11:36:00 AM

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Updated Disease Classification System Adopted by the World Health Organization

8/1/2019 7:19:00 AM

On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

8/1/2019 7:09:00 AM

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.

More News